Pharmaceutical

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.

Mar 20, 2024 - 00:00
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.
Read the original article

Tags:

Previous Article

Microsoft and NVIDIA expand collaboration in healthcare innovation

Next Article

No Proof of Brain Injury in ‘Havana Syndrome’ Patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Discovery that chimpanzees go through menopause challenges ‘grandmother hypothesis’

Discovery that chimpanzees go through menopause challen...

Oct 26, 2023

Telix raises $398m to advance kidney and brain cancer radiotherapies

Telix raises $398m to advance kidney and brain cancer r...

Jul 24, 2024

With arrival of breakthrough therapies, a rare disease group reconsiders the possible — and its mission

With arrival of breakthrough therapies, a rare disease ...

Mar 28, 2023